Melanoma treatments have advanced rapidly, particularly with the introduction of immunotherapies that help the immune system recognise and target cancer. Yet, many patients do not respond, experience significant side effects or see their disease return. Professor Sophia Karagiannis, a cancer immunology researcher at King’s College London, is dedicated to understanding these challenges and improving the precision, safety and effectiveness of melanoma treatment. Drawing on her advanced training in immunology and early experience in the biotechnology and pharmaceutical sectors, she gained direct insight into how scientific discoveries progress into real therapies, expertise that now drives her development of innovative antibody-based treatments.
To continue reading this article, please
sign in or
register.